Migraine prophylaxis-all just antibodies? Medical and nonmedical migraine preventive treatment in times of CGRP antibodies

被引:0
|
作者
Hamann, Till [1 ]
Kamm, Katharina [2 ]
Kropp, Peter [3 ]
Rimmele, Florian [1 ]
Juergens, Tim Patrick [1 ]
机构
[1] Univ Med Rostock, Klin & Poliklin Neurol, Kopfschmerzzentrum Nord Ost, Gehlsheimer Str 20, D-18147 Rostock, Germany
[2] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Neurol Klin & Poliklin, Oberbayr Kopfschmerzzentrum, Munich, Germany
[3] Univ Med Rostock, Inst Med Psychol & Med Soziol, Kopfschmerzzentrum Nord Ost, Rostock, Germany
来源
SCHMERZ | 2020年 / 34卷 / 06期
关键词
Receptors; calcitonin gene-related peptide; Immunotherapy; Analgesics; Prevention; Medication overuse; CORTICAL SPREADING DEPRESSION; PREVALENCE; TOPIRAMATE; HEADACHE; BURDEN;
D O I
10.1007/s00482-020-00500-x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background Migraine is a frequently underdiagnosed disease that is associated with a high burden on affected patients. There are a variety of prophylactic treatment options available, that have been expanded with the introduction of the CGRP-(receptor-)antibodies. Objectives Status of pharmacologic and nonpharmacologic preventive treatment in migraine therapy. Methods Analysis and evaluation of internationally published articles concerning preventive treatment of episodic and chronic migraine. Results There are many approved medications for migraine prophylaxis with different evidence. The possibilities were further expanded with CGRP antibodies. Comparative studies of the new antibodies with previous prophylactic drugs have not yet been published, so it's unclear whether the antibodies are therapeutically superior. What should be emphasized is their rapid onset of action and their good tolerance. Basically, an individual choice of prophylaxis, which is based on affectedness, comorbidities and comedication, makes sense. In addition, a combination with nondrug measures is always mandatory. Conclusions A variety of medicinal and non-medicinal measures are available for the treatment of migraine, which should be used multimodally.
引用
收藏
页码:476 / 485
页数:10
相关论文
共 50 条
  • [1] CGRP antibodies in migraine prophylaxis The new standard in migraine treatment?
    Hamann, Till
    Rimmele, Florian
    Juergens, Tim Patrick
    SCHMERZ, 2022, 36 (01): : 59 - 72
  • [2] CGRP Antibodies as Prophylaxis in Migraine
    Edvinsson, Lars
    CELL, 2018, 175 (07) : 1719 - 1719
  • [3] Migräneprophylaxe – alles nur noch Antikörper?Medikamentöse und nicht-medikamentöse Migräneprophylaxe in Zeiten der CGRP-AntikörperMigraine prophylaxis—all just antibodies?Medical and nonmedical migraine preventive treatment in times of CGRP antibodies
    Till Hamann
    Katharina Kamm
    Peter Kropp
    Florian Rimmele
    Tim Patrick Jürgens
    Der Schmerz, 2020, 34 (6) : 476 - 485
  • [4] CGRP antagonists and antibodies for the treatment of migraine
    Vecsei, Laszlo
    Szok, Delia
    Csati, Anett
    Tajti, Janos
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (01) : 31 - 41
  • [5] CGRP antibodies in the prophylactic treatment of migraine
    Sipkova, J.
    Nezadal, T.
    Ctrnacta, D.
    Bajacek, M.
    Dvorak, J.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2022, 85 (03) : 248 - 256
  • [6] Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine
    Nicol, Kelly S.
    Burkett, John G.
    CURRENT PAIN AND HEADACHE REPORTS, 2025, 29 (01)
  • [7] CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine
    Heike Israel
    Lars Neeb
    Uwe Reuter
    Current Pain and Headache Reports, 2018, 22
  • [8] CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine
    Israel, Heike
    Neeb, Lars
    Reuter, Uwe
    CURRENT PAIN AND HEADACHE REPORTS, 2018, 22 (05)
  • [9] Monoclonal antibodies against CGRP for the treatment of migraine
    Alberto Choreno-Parra, Jose
    Carnalla-Cortes, Martha
    Martinez-Zuniga, Nayeli
    Guadarrama-Ortiz, Parmenides
    REVISTA MEXICANA DE NEUROCIENCIA, 2018, 19 (04): : 45 - 61
  • [10] Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies
    Negro, Andrea
    Martelletti, Paolo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (08) : 769 - 776